PET Faces A No-Win Situation At MCAC Review Of Alzheimer’s Treatment
This article was originally published in The Gray Sheet
Executive Summary
The Medicare Coverage Advisory Committee Diagnostic Imaging Panel's rejection of PET imaging for use in treating Alzheimer's disease demonstrates that diagnostic coverage reviews in the future may depend as much on the treatment in question as the diagnostic itself
You may also be interested in...
CMS Says No To PET For Alzheimer’s, But Leaves Door Open For Future Studies
CMS continues to support research on FDG-PET in the diagnosis of Alzheimer's disease (AD), despite an April 16 non-coverage decision
CMS Says No To PET For Alzheimer’s, But Leaves Door Open For Future Studies
CMS continues to support research on FDG-PET in the diagnosis of Alzheimer's disease (AD), despite an April 16 non-coverage decision
NIA Alzheimer’s Imaging Project Would Require Industry, Academia Funding
A proposed Alzheimer's disease neuroimaging program being spearheaded by the National Institute on Aging would cost roughly $60 mil. over five years, according to NIA